Determinants of interactions of a novel next-generation gabapentinoid NVA1309 and mirogabalin with the Cav[alpha]2[delta]-1 subunit

NVA1309 is a non-brain penetrant next-generation gabapentinoid shown to bind Cav[alpha]2[delta] at R243 within a triple Arginine motif forming the binding site for gabapentin and pregabalin. In this study we have compared the effects of NVA1309 with Mirogabalin, a gabapentinoid drug with higher affinity for the voltage-gated calcium channel subunit Cav[alpha]2[delta]-1 than pregabalin which is approved for post-herpetic neuralgia in Japan, Korea and Taiwan. Both NVA1309 and mirogabalin inhibit Cav2.2 currents in vitro and decrease Cav2.2 plasma membrane expression with higher efficacy than pregabalin. Mutagenesis of the classical binding residue arginine R243 and the newly identified binding residue lysine K615 reverse the effect of mirogabalin on Cav2.2 current, but not that of NVA1309. Keywords: Mirogabalin, Gabapentinoids, Calcium channel, Neuropathic pain, Cav[alpha]2[delta]